

**Outline of Consolidated Financial Results  
for the 2nd Quarter Ended September 30, 2015**

**NIPPON SHINYAKU CO., LTD.**



# FY2015 2Q Summary

(Million yen)

|   | 2QFY2014 |        | 2QFY2015 |        | YoY Change |      |
|---|----------|--------|----------|--------|------------|------|
|   | Results  | Ratio  | Results  | Ratio  | Amt        | %    |
| Net sales                                       | 36,470   | 100.0% | 39,413   | 100.0% | 2,942      | 8.1% |
| Operating income                                | 2,033    | 5.6%   | 2,110    | 5.4%   | 76         | 3.7% |
| Ordinary income                                 | 2,272    | 6.2%   | 2,335    | 5.9%   | 63         | 2.8% |
| Net income attributable to owners of the parent | 1,440    | 4.0%   | 1,523    | 3.9%   | 82         | 5.7% |

## Topics

- ◆ Launch NS-24(Onetram tablet 100mg) ... (Jun.)
- ◆ Launch ACT-064992(Opsumit tablet 10mg) ... (Jun.)
- ◆ Selexipag: Listed of 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension ... (Aug.)
- ◆ NS-065: Selected by the Japanese MHLW as one of the projects for Sakigake designation ... (Oct.)



# Segmental Review

## — Pharmaceuticals —

(Million yen)

|   | 2QFY2014      |               | 2QFY2015      |               | YoY Change   |             |
|---|---------------|---------------|---------------|---------------|--------------|-------------|
|   | Results       | Ratio         | Results       | Ratio         | Amt          | %           |
| Ethical drugs   | 29,011        | 98.5%         | 31,392        | 97.4%         | 2,380        | 8.2%        |
| Revenues from the licensing of industrial property rights | 64            | 0.2%          | 115           | 0.4%          | 50           | 78.0%       |
| Others  | 378           | 1.3%          | 736           | 2.2%          | 358          | 94.7%       |
| <b>Net sales</b>  | <b>29,454</b> | <b>100.0%</b> | <b>32,244</b> | <b>100.0%</b> | <b>2,789</b> | <b>9.5%</b> |

Others:API ,Contract manufacturing business and Promotion fee

### Increase in sales:

- **Zalutia ( +1,567million yen ,+208.0% )**  
( urinary disorder caused by benign prostatic hyperplasia)
- **Vidaza ( +1,017 million yen, +20.2% )**  
( myelodysplastic syndromes )
- **Tramal, Onetram (+942million yen, +81.5% )**  
( cancer pain,chronic pain)
- **Lunabell(+493million yen, +16.5% )**  
( Remedy for dysmenorrhea )

etc

### Decrease in sales:

- **Eviprostat ( -622 million yen, -22.2% )**  
( Remedy for benign prostatic hyperplasia )
- **GaslonN ( -380 million yen, -19.5% )**  
( gastric ulcer, gastritis)

etc




# New Products Review

## — Pharmaceuticals —

### ◆ Sales Growth of New Products Group

| New Products   | FY2014 2Q     | FY2015 2Q     | Y on Y Change |
|----------------|---------------|---------------|---------------|
| Vidaza         | 5,048         | 6,066         | +20.2%        |
| Lunabell       | 2,999         | 3,493         | +16.5%        |
| Zalutia        | 753           | 2,320         | +208.0%       |
| Tramal·Onetram | 1,156         | 2,098         | +81.5%        |
| Adcirca        | 1,440         | 1,765         | +22.5%        |
| Cialis         | 1,737         | 1,687         | -2.9%         |
| Erizas         | 399           | 463           | +16.1%        |
| Regtect        | 345           | 435           | +26.2%        |
| <b>Total</b>   | <b>13,881</b> | <b>18,330</b> | <b>+32.1%</b> |






# Segmental Review

## — Pharmaceuticals —

**Net sales 32,244 million yen**

**Year-on-Year change  
+ 2,789 million yen ( +9.5% )**

**35,000**  
(Million yen)





# Segmental Review

## — Functional Food —

(Million yen)

|                         | 2QFY2014 |        | 2QFY2015 |        | YoY Change |       |
|-------------------------|----------|--------|----------|--------|------------|-------|
|                         | Results  | Ratio  | Results  | Ratio  | Amt        | %     |
| Health food ingredients | 352      | 5.0%   | 419      | 5.9%   | 66         | 18.9% |
| Preservatives           | 916      | 13.1%  | 923      | 12.9%  | 7          | 0.8%  |
| Protein preparations    | 3,836    | 54.7%  | 3,873    | 54.0%  | 37         | 1.0%  |
| Nutritional ingredients | 1,155    | 16.5%  | 1,222    | 17.0%  | 66         | 5.8%  |
| Others                  | 754      | 10.7%  | 730      | 10.2%  | -24        | -3.2% |
| Net sales               | 7,015    | 100.0% | 7,169    | 100.0% | 153        | 2.2%  |




# Segmental Review

## — Functional Food —

**Net sales 7,169 million yen**

**Year-on-Year change**  
**+ 153 million yen ( +2.2% )**

10,000  
(Million yen)






# Net Sales

**Net sales 39,413 million yen**

**Year-on-Year change  
+ 2,942 million yen ( +8.1% )**

50,000  
(Million yen)







# Consolidated Statements of Income ①

(Million yen)

|                           | 2QFY2014      |               | 2QFY2015      |               | YoY Change   |             |
|---------------------------|---------------|---------------|---------------|---------------|--------------|-------------|
|                           | Results       | Ratio         | Results       | Ratio         | Amt          | %           |
| <b>Revenue</b>            |               |               |               |               |              |             |
| <b>Net sales</b>          | <b>36,470</b> | <b>100.0%</b> | <b>39,413</b> | <b>100.0%</b> | <b>2,942</b> | <b>8.1%</b> |
| Pharmaceuticals           | 29,454        | 80.8%         | 32,244        | 81.8%         | 2,789        | 9.5%        |
| Functional Food           | 7,015         | 19.2%         | 7,169         | 18.2%         | 153          | 2.2%        |
| <b>Operating expenses</b> | <b>34,436</b> | <b>94.4%</b>  | <b>37,303</b> | <b>94.6%</b>  | <b>2,866</b> | <b>8.3%</b> |
| Cost of sales             | 19,529        | 53.5%         | 21,569        | 54.7%         | 2,039        |             |
| SG&A expenses             | 10,663        | 29.3%         | 11,008        | 27.9%         | 345          |             |
| R&D expenses              | 4,243         | 11.6%         | 4,725         | 12.0%         | 481          |             |
| <b>Operating income</b>   | <b>2,033</b>  | <b>5.6%</b>   | <b>2,110</b>  | <b>5.4%</b>   | <b>76</b>    | <b>3.7%</b> |



# Consolidated Statements of Income ②

(Million yen)

|   | 2QFY2014 |       | 2QFY2015 |       | YoY Change |       |
|---|----------|-------|----------|-------|------------|-------|
|   | Results  | Ratio | Results  | Ratio | Amt        | %     |
| Operating income                                | 2,033    | 5.6%  | 2,110    | 5.4%  | 76         | 3.7%  |
| Non-operating income                            | 442      | 1.2%  | 483      | 1.2%  | 41         | 9.4%  |
| Non-operating expenses                          | 203      | 0.6%  | 258      | 0.7%  | 54         | 26.7% |
| Ordinary income                                 | 2,272    | 6.2%  | 2,335    | 5.9%  | 63         | 2.8%  |
| Income taxes, etc                               | 831      | 2.3%  | 812      | 2.1%  | -19        | -2.3% |
| Net income attributable to owners of the parent | 1,440    | 4.0%  | 1,523    | 3.9%  | 82         | 5.7%  |



# Consolidated Balance Sheet

(Million yen)

|                     | FY2014     | FY2015     | Change |   | FY2014     | FY2015     | Change |
|---------------------|------------|------------|--------|---|------------|------------|--------|
|                     | 4Q Results | 2Q Results | Amt    |   | 4Q Results | 2Q Results | Amt    |
| <b>Assets</b>       | 129,757    | 127,652    | -2,104 | <b>Liabilities</b>                      | 28,550     | 25,889     | -2,660 |
| (Current assets)    | 80,422     | 78,026     | -2,395 | (Current liabilities)                   | 17,770     | 15,797     | -1,973 |
| (Fixed assets)      | 49,334     | 49,625     | 291    | (Long-term liabilities)                 | 10,779     | 10,092     | -687   |
|                     |            |            |        | <b>Net assets</b>                       | 101,207    | 101,763    | 555    |
| <b>Total Assets</b> | 129,757    | 127,652    | -2,104 | <b>Total liabilities and net assets</b> | 129,757    | 127,652    | -2,104 |



# Consolidated Statements of Cash Flows

(Million yen)

|   | 2QFY2014 | 2QFY2015 | YoY Change |
|---|----------|----------|------------|
|   | Results  | Results  | Amt        |
| Operating activities                        | 1,690    | -271     | -1,961     |
| Investing activities                        | -2,367   | -1,554   | 813        |
| Financing activities                        | -893     | -916     | -22        |
| Cash and cash equivalents at end of quarter | 19,647   | 19,192   | -454       |

Cash and cash equivalents at end of quarter : -2,721 Million yen (YoY FY2014)



# Capital Investment

## Capital Investment and Depreciation

(Million yen)

|                    | 2QResults |        |         |
|--------------------|-----------|--------|---------|
|                    | FY2014    | FY2015 | Amt Chg |
| Capital investment | 808       | 1,157  | 349     |
| Depreciation       | 1,294     | 1,184  | -110    |

## Breakdown of Capital Investment

(Million yen)

|   | 2QResults  |              |            |
|---|------------|--------------|------------|
|   | FY2014     | FY2015       | Amt Chg    |
| <NIPPON SHINYAKU CO.,LTD.>                            | 762        | 1,102        | 340        |
| Production  | 381        | 345          | -36        |
| R&D   | 316        | 677          | 360        |
| (Manufacturing facility for<br>investigational drugs) | (0)        | (585)        | (585)      |
| Others  | 64         | 80           | 15         |
| <Sioe Pharmaceutical Co.,Ltd.>                        | 8          | 25           | 17         |
| <Tajima Shokuhin Kogyo Co.,Ltd.>                      | 37         | 29           | -7         |
| <b>Total capital investment</b>                       | <b>808</b> | <b>1,157</b> | <b>349</b> |



# Business Forecast for FY2015

(Million yen)


|   | FY2014  |        | FY2015   |        | YoY Change |       |
|---|---------|--------|----------|--------|------------|-------|
|   | Results | Ratio  | Forecast | Ratio  | Amt        | %     |
| Net sales                                       | 79,991  | 100.0% | 87,000   | 100.0% | 7,009      | 8.8%  |
| Operating income                                | 8,562   | 10.7%  | 9,300    | 10.7%  | 738        | 8.6%  |
| Ordinary income                                 | 8,928   | 11.2%  | 9,500    | 10.9%  | 572        | 6.4%  |
| Net income attributable to owners of the parent | 5,882   | 7.4%   | 6,700    | 7.7%   | 818        | 13.9% |



# Segmental Forecast — Pharmaceuticals —

**Net sales 73,100 million yen**

**Year-on-Year change  
+6,760 million yen ( +10.2% )**





# Segmental Forecast

## — Pharmaceuticals —

(Million yen)

|  | FY2014        |               | FY2015        |               | YoY Change   |              |
|--|---------------|---------------|---------------|---------------|--------------|--------------|
|  | Results       | Ratio         | Forecast      | Ratio         | Amt          | %            |
| <b>Ethical drugs</b>   | <b>62,898</b> | <b>94.8%</b>  | <b>66,300</b> | <b>90.7%</b>  | <b>3,402</b> | <b>5.4%</b>  |
| <b>Revenues from the licensing of industrial property rights</b> | <b>2,510</b>  | <b>3.8%</b>   | <b>5,000</b>  | <b>6.8%</b>   | <b>2,490</b> | <b>99.1%</b> |
| <b>Others</b>  | <b>930</b>    | <b>1.4%</b>   | <b>1,800</b>  | <b>2.5%</b>   | <b>870</b>   | <b>93.5%</b> |
| <b>Net sales</b>   | <b>66,340</b> | <b>100.0%</b> | <b>73,100</b> | <b>100.0%</b> | <b>6,760</b> | <b>10.2%</b> |

Others: API , Contract manufacturing business and Promotion fee






# Segmental Forecast

## — Functional Food —

20,000  
(Million yen)

**Net sales 13,900 million yen**

**Year-on-Year change**  
**+ 249 million yen ( +1.8% )**





# Segmental Forecast

## — Functional Food —

(Million yen)

|                         | FY2014        |               | FY2015        |               | YoY Change |             |
|-------------------------|---------------|---------------|---------------|---------------|------------|-------------|
|                         | Results       | Ratio         | Forecast      | Ratio         | Amt        | %           |
| Health food ingredients | 747           | 5.5%          | 830           | 6.0%          | 83         | 11.0%       |
| Preservatives           | 1,886         | 13.8%         | 1,900         | 13.7%         | 14         | 0.7%        |
| Protein preparations    | 7,290         | 53.4%         | 7,450         | 53.6%         | 160        | 2.2%        |
| Nutritional ingredients | 2,295         | 16.8%         | 2,320         | 16.7%         | 25         | 1.1%        |
| Others                  | 1,431         | 10.5%         | 1,400         | 10.0%         | -31        | -2.2%       |
| <b>Net sales</b>        | <b>13,651</b> | <b>100.0%</b> | <b>13,900</b> | <b>100.0%</b> | <b>249</b> | <b>1.8%</b> |



# Consolidated Statements of Income (Forecast) (1)

(Million yen)

|                           | FY2014  |        | FY2015   |        | YoY Change |       |
|---------------------------|---------|--------|----------|--------|------------|-------|
|                           | Results | Ratio  | Forecast | Ratio  | Amt        | %     |
| <b>Revenue</b>            |         |        |          |        |            |       |
| <b>Net sales</b>          | 79,991  | 100.0% | 87,000   | 100.0% | 7,009      | 8.8%  |
| Pharmaceuticals           | 66,340  | 82.9%  | 73,100   | 84.0%  | 6,760      | 10.2% |
| Functional Food           | 13,651  | 17.1%  | 13,900   | 16.0%  | 249        | 1.8%  |
| <b>Operating expenses</b> | 71,429  | 89.3%  | 77,700   | 89.3%  | 6,271      | 8.8%  |
| Cost of sales             | 41,226  | 51.5%  | 44,700   | 51.4%  | 3,474      |       |
| SG&A expenses             | 21,233  | 26.6%  | 22,600   | 26.0%  | 1,367      |       |
| R&D expenses              | 8,968   | 11.2%  | 10,400   | 11.9%  | 1,432      |       |
| <b>Operating income</b>   | 8,562   | 10.7%  | 9,300    | 10.7%  | 738        | 8.6%  |



# Consolidated Statements of Income (Forecast) (2)

(Million yen)

|   | FY2014  |       | FY2015   |       | YoY Change |        |
|---|---------|-------|----------|-------|------------|--------|
|   | Results | Ratio | Forecast | Ratio | Amt        | %      |
| Operating income                                | 8,562   | 10.7% | 9,300    | 10.7% | 738        | 8.6%   |
| Non-operating income                            | 939     | 1.2%  | 900      | 1.0%  | -39        | - 4.2% |
| Non-operating expenses                          | 573     | 0.7%  | 700      | 0.8%  | 127        | 22.0%  |
| Ordinary income                                 | 8,928   | 11.2% | 9,500    | 10.9% | 572        | 6.4%   |
| Income taxes, etc                               | 3,046   | 3.8%  | 2,800    | 3.2%  | -246       | - 8.1% |
| Net income attributable to owners of the parent | 5,882   | 7.4%  | 6,700    | 7.7%  | 818        | 13.9%  |



# Dividends Forecast

|                        |          | FY2014 | FY2015 |
|------------------------|----------|--------|--------|
| Dividends per share    | Interim  | ¥12    | ¥14    |
|                        | Year-end | ¥13    | ¥14    |
|                        | Annual   | ¥25    | ¥28    |
| EPS                    |          | ¥87.26 | ¥99.45 |
| Dividends payout ratio |          | 28.7 % | 28.2 % |



# Capital Investment Plan

## Capital Investment and Depreciation

(Million yen)

|                    | FY2014<br>Results | FY2015<br>Forecast | Amt Chg |
|--------------------|-------------------|--------------------|---------|
| Capital investment | 1,239             | 4,000              | 2,761   |
| Depreciation       | 2,665             | 2,500              | -165    |

## Breakdown of Capital investment

(Million yen)

|   | FY2014<br>Results | FY2015<br>Forecast | Amt Chg      |
|---|-------------------|--------------------|--------------|
| <NIPPON SHINYAKU CO.,LTD.>                              | 1,160             | 3,850              | 2,690        |
| Production  | 510               | 700                | 190          |
| (Manufacturing facility for<br>highly active medicines) | (0)               | (100)              | (100)        |
| R&D   | 508               | 2,600              | 2,092        |
| (Manufacturing facility for<br>investigational drugs)   | (19)              | (1,850)            | (1,831)      |
| Others  | 140               | 550                | 410          |
| <Sioe Pharmaceutical Co.,Ltd.>                          | 14                | 50                 | 36           |
| <Tajima Shokuhin Kogyo Co.,Ltd.>                        | 64                | 100                | 36           |
| <b>Total capital investment</b>                         | <b>1,239</b>      | <b>4,000</b>       | <b>2,761</b> |

# Status of Development Pipeline



# R&D Pipeline(Domestic)

| Code No.<br>(Generic name)<br><Origin>  | Application<br>type | Indications  | Stage                   | FY2013 | FY2014 | FY2015        | FY2016 |
|---|---------------------|--|-------------------------|--------|--------|---------------|--------|
| GA101<br>(obinutuzumab)<br><in-license> | NME                 | indolent non-Hodgkin's<br>lymphoma<br>aggressive non-Hodgkin's<br>lymphoma | P III                   |        |        |               |        |
| NS-304<br>(selexipag)<br><in-house>     | NME                 | pulmonary arterial<br>hypertension   | Preparation<br>For NDA  |        |        | NDA<br>Filing |        |
|   |                     | chronic thromboembolic<br>pulmonary hypertension                           | P II                    |        |        |               |        |
|   |                     | arteriosclerosis obliterans  | P II                    |        |        |               |        |
| NS-141<br><in-house>                    | NME                 | pruritus associated with<br>cutaneous disease                              | P II                    |        |        |               |        |
| NS-986<br><in-license>                  | NME                 | nocturia   | P II                    |        |        | P II          |        |
| NS-065/<br>NCNP-01<br><in-house>        | NME                 | duchenne muscular dystrophy  | Preparation<br>For P II |        |        |               |        |
| NS-580<br><in-house>                    | NME                 | endometriosis  | P I                     |        |        |               |        |





# R&D Pipeline (Overseas)

| Code No.<br>(Generic name)<br><Origin> | Application type | Indications                     | Stage                           | FY2013                | FY2014     | FY2015 | FY2016     |
|--|------------------|---------------------------------|---------------------------------|-----------------------|------------|--------|------------|
| NS-304<br>(selexipag)<br><in-house>    | NME              | pulmonary arterial hypertension | US/EU<br>NDA Filing             | Actelion<br>P III     | NDA Filing |        |            |
| prulifloxacin<br><in-house>            | NME              | bacterial infections            | China<br>Preparation<br>For NDA | Lee's Pharma<br>P III |            |        | NDA Filing |
| NS-018<br><in-house>                   | NME              | myelofibrosis                   | US<br>P I / II                  | P I / II              |            |        |            |



# GA101 (Obinutuzumab)

- Treatment for non-Hodgkin's lymphoma -

|                     |   |
|---------------------|---|
| Development Phase   | <ul style="list-style-type: none"><li>▪ Overseas: PIII (Multinational studies, Roche)</li><li>▪ Japan: PIII (Multinational studies)</li></ul> |
| Origin              | [Nov. 2012]<br>Licensed-in from: Chugai Pharmaceutical Co., Ltd.  |
| Development         | Co-development in Japan: Chugai Pharmaceutical Co., Ltd.  |
| Indication          | <ul style="list-style-type: none"><li>▪ Indolent non-Hodgkin's lymphoma</li><li>▪ Aggressive non-Hodgkin's lymphoma</li></ul>                 |
| Mechanism of action | Anti-CD20 monoclonal antibody   |
| Dosage form         | Injection   |
| Feature             | Anti-CD20 monoclonal antibody, increased antibody-dependent cellular cytotoxicity (ADCC) activity and direct cytotoxicity                     |



# NS-304 (Selexipag)

- Treatment for pulmonary hypertension -

|                     |   |
|---------------------|---|
| Development phase   | <ul style="list-style-type: none"><li>• Overseas: NDA filing</li><li>• Japan : Preparation for NDA</li></ul>  |
| Origin              | <ul style="list-style-type: none"><li>• Nippon Shinyaku</li></ul>   |
| Development         | <p>[Apr. 2008]</p> <ul style="list-style-type: none"><li>• Licensed-out to (outside Japan):<br/>Actelion Pharmaceuticals Ltd.(Switzerland)</li><li>• Co-development in Japan:<br/>Actelion Pharmaceuticals Japan Ltd.</li></ul>   |
| Indication          | <ul style="list-style-type: none"><li>• Pulmonary arterial hypertension</li><li>• Chronic thromboembolic pulmonary hypertension</li><li>• Arteriosclerosis obliterans</li></ul>   |
| Dosage form         | Tablet  |
| Mechanism of action | Selective PGI <sub>2</sub> receptor agonist   |
| Feature             | <p>Long-acting oral drug<br/>Orphan drug designation by EMA [Aug.2005],<br/>FDA [Apr.2010] and MHLW [Sep.2014]<br/>Listed of 2015 ESC/ERS Guidelines for the diagnosis<br/>and treatment of pulmonary hypertension [Aug.2015]</p> |



# NS-141

- Anti-pruritic drug -

|                   |  |
|-------------------|--|
| Development phase | Additional PII (exploratory study)   |
| Origin            | Nippon Shinyaku  |
| Development       | Nippon Shinyaku  |
| Indication        | Pruritus associated with cutaneous disease   |
| Dosage form       | Ointment   |
| Feature           | <ul style="list-style-type: none"><li>▪ New mechanism of action (not antihistaminic)</li><li>▪ Effective against intractable pruritus which cannot be treated by existing treatments</li></ul> |



# NS-986

## - Treatment for nocturia -

|                             |   |
|-----------------------------|---|
| Development phase           | PII (exploratory study) completed   |
| Origin                      | [Mar.2013]<br>Licensed-in from:<br>Dainippon Sumitomo Pharma Co., Ltd.  |
| Development                 | Nippon Shinyaku   |
| Indication                  | Nocturia  |
| Dosage form/ Dosing regimen | Tablet  |
| Mechanism of action         | <ul style="list-style-type: none"><li>▪ Muscarinic receptor antagonist</li><li>▪ Na<sup>+</sup> channel blocker</li></ul>                             |
| Feature                     | <ul style="list-style-type: none"><li>▪ Rapid onset of effect</li><li>▪ Improvement in nocturia refractory to existing antimuscarinic drugs</li></ul> |



# NS-065/NCNP-01

## - Treatment for Duchenne Muscular Dystrophy -

|                     |  |
|---------------------|--|
| Development Phase   | An investigator-initiated clinical trial completed<br>Preparation for PII  |
| Origin              | Nippon Shinyaku  |
| Development         | Nippon Shinyaku  |
| Indication          | Duchenne Muscular Dystrophy  |
| Dosage form         | Infusion   |
| Mechanism of action | Exon Skipping  |
| Feature             | <ul style="list-style-type: none"><li>• Improvement in symptoms and prevention of the disease progression by recovery of Dystrophin protein expression</li><li>• morpholino based oligonucleotide with possible high safety profile and maximized activity</li><li>• Selected by the Japanese MHLW as one of the projects for Sakigake designation[Oct.2015]</li></ul> |



# NS-580

## - Treatment for endometriosis -

|                     |  |
|---------------------|--|
| Development Phase   | PI   |
| Origin              | Nippon Shinyaku  |
| Development         | Nippon Shinyaku  |
| Indication          | Endometriosis  |
| Dosage form         | Oral agent   |
| Mechanism of action | Inhibition of membrane-associated prostaglandin E synthase-1   |
| Feature             | Treatment for endometriosis without hormonal effect and with possible analgesic potency and improvement effect on endometriotic lesions. |



# Prulifloxacin

- Quinolone antibacterial -

## Japan

| Licensee                       | Development phase                     |
|--------------------------------|---------------------------------------|
| • Meiji Seika Pharma Co., Ltd. | • Launch (Dec. 2002) / Sword® Tablets |

## Overseas

| Licensee   | Development phase   |
|--|---|
| • Angelini (Italy)                               | <ul style="list-style-type: none"> <li>• Approval (Sep. 2004)</li> <li>• Launch in Italy (Nov. 2004)</li> <li>• Approval in European countries (Apr. 2005)</li> </ul>                             |
| • Lee's Pharmaceutical Holdings Ltd. (Hong Kong) | • China Preparation For NDA   |
| • Algorithm (Lebanon)                            | <ul style="list-style-type: none"> <li>• Launch in Lebanon (Jan. 2012)</li> <li>• NDA filing in 7 countries and preparation for NDA in 2 countries of the Middle East and North Africa</li> </ul> |





# NS-018

## - Treatment for myelofibrosis -

|                     |   |
|---------------------|---|
| Development Phase   | Overseas (USA): PI/II   |
| Origin              | Nippon Shinyaku   |
| Development         | Nippon Shinyaku   |
| Indication          | Myelofibrosis   |
| Dosage form         | Tablet  |
| Mechanism of action | JAK2 tyrosine kinase inhibitor  |
| Feature             | <ul style="list-style-type: none"><li>• Highly selective for active form of JAK2 tyrosine kinase</li><li>• Possibly best-in-class treatment for myelofibrosis</li></ul> |



# Safe Harbor Statement

- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion or failure of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination, obtaining regulatory approvals; domestic and foreign social security reforms; trends toward healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and competition with others.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This English presentation was translated from the original Japanese version.  
In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.